Rabies Vaccine BP

  • Name:

    Rabies Vaccine BP

  • Company:
    info
  • Active Ingredients:

    Rabies Vaccine BP

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 11/02/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 11/2/2019

Click on this link to Download PDF directly

Sanofi Pasteur

Sanofi Pasteur

Company Products

Medicine NameActive Ingredients
Medicine Name AVAXIM Active Ingredients Inactivated Hepatitis A Vaccine
Medicine Name Quadrivalent Influenza vaccine (split virion, inactivated) Active Ingredients Influenza vaccine (split virion, inactivated)
Medicine Name Rabies Vaccine BP Active Ingredients Rabies Vaccine BP
Medicine Name REVAXIS Active Ingredients Diphtheria Vaccine, Poliomyelitis Vaccine, Tetanus Vaccine
Medicine Name STAMARIL Active Ingredients Yellow Fever Vaccine
Medicine Name TYPHIM Vi Active Ingredients Vi Capsular Polysaccharide vaccine
Medicine Name ViATIM Active Ingredients Hepatitis A Vaccine, Purified Inactivated, for Adults, Typhoid Vaccine
1 - 0 of 7 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 11 February 2019 PIL

Reasons for updating

  • Change to section 6 - date of revision
  • Change to further information section

Updated on 11 February 2019 SmPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated due to a change of supplier of the prefilled syringe of diluent. Section 6.5 has been updated to describe the new syringe presentation and composition, and section 6.6 has been updated to give specific handling instructions for the new syringe.

Updated on 19 January 2018 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 19 January 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 19 January 2018 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 

MAH change of address from 2 avenue Pont Pasteur 69007 Lyon France to 14 Espace Henry Vallée 69007 Lyon France

Updated on 19 January 2018 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 5 April 2017 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Type IAin - SmPC update further to PSUSA_00009277_201603

Updated on 1 February 2017 PIL

Reasons for updating

  • Change of distributor details

Updated on 17 January 2017 SmPC

Reasons for updating

  • Company name change or merger

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Sanofi Pasteur MSD company name changed to Sanofi Pasteur

Updated on 16 January 2017 PIL

Reasons for updating

  • Company name change or merger

Updated on 16 March 2015 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

In section 4.8 (undesirable effects), advice regarding how to report side effects in Ireland has been added.

Updated on 16 March 2015 PIL

Reasons for updating

  • Addition of information on reporting a side effect.

Updated on 10 January 2013 PIL

Reasons for updating

  • Change to dosage and administration

Updated on 10 January 2013 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.2: updated section 4.2 to bring it into line with the corresponding section of the Company Core Data Sheet (CCDS) for Rabies Vaccine.

 

  • To amend the primary vaccination series for prophylaxis to introduce Day 21 as an alternative to Day 28 for the third vaccine dose.

  • To change the recommendation for timing of booster doses: from at 2 to 3 year intervals, to one year after the primary series followed by subsequent doses every 5 years. A recommendation for regular serology testing of neutralising antibodies in individuals at an increased risk of exposure to rabies virus has also been added.
  • To change the treatment schedule for previously immunised subjects from 2 doses given on Day 0 and Day 3-7 to 2 doses given on Day 0 and Day 3.
  • To change the treatment schedule for individuals without adequate prophylaxis from a 6 dose course ending on Day 90 to a 5 dose course ending on Day 30 (or Day 28 as per WHO recommendations).

Section 4.4: Included the following sentence - If Rabies Immunoglobulin is indicated in addition to Rabies Vaccine BP, then it must be administered at a different anatomical site to the vaccination site.

Section 10: revised date to November 2012

 

Updated on 22 December 2010 SmPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

catalent and term strelisation

Updated on 10 July 2009 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Addition of a warning on the risk of apnoea in very premature infants following vaccination, updates to section 4.4 and section 4.8.

Updated on 6 July 2009 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 25 March 2009 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 6.1 - List of excipients
  • Change to section 6.3 - Shelf life
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to section 2 qualitative and quantitative composition

Re-worded to state amount of active following reconstitution.

Change to section 3 pharmaceutical form

Visual description of the powder and solvent has been included.

Change to section 6.1 List of excipients

Ph. Eur. Title of Human Albumin Solution included.

Change to section 6.3 Shelf life

Statement regarding the in-use shelf life of the reconstituted product added.

Change to section 6.5 Nature and contents of container

The heading Lyophilised vaccine was amended to Powder

Statement re-worded to read Not all pack presentations may be marketed

Change to section 6.6 Instructions for use/handling

Update to statement regarding disposal of the product

Change to section 9 Date of renewal of authorisation

Updated following approval of the renewal

Change to section 10 Date of partial revision of the text

Date of revision updated.

Updated on 15 October 2008 PIL

Reasons for updating

  • Change due to user-testing of patient information
  • Change to date of revision

Updated on 18 December 2007 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to section 4.8, addition of Guillain-Barré syndrome and paresis.

Updated on 18 December 2007 PIL

Reasons for updating

  • Change to side-effects

Updated on 9 March 2007 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.1 - List of excipients
  • Change to section 6.4 - Special precautions for storage
  • Change to marketing authorisation holder address
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 2, 3, 4.6, 6.1 and 6.4:  Updated in line with the QRD template.

Section 4.2:  Removal of ‘deep subcutaneous’ as a route of administration.
 
Section 4.3: Updated contraindications on pre and post exposure to the Rabies virus.
 
Section 4.4:  Added information on beapropiolactone, neomycin and administration to persons with bleeding disorders or receiving anticoagulants.
 
Section 4.5:  Added information on administration to patients receiving corticosteroids or immunosuppressive treatment.
 
Section 4.8: Updated in line with the QRD template and addition of further side effects including lymphadenopathy, diarrhoea, dyspnoea and wheezing.
 
Section 7: Updated the address of the Marketing Authorisation Holder
 
Section 10: Changed date of revision of the text to February 2007

 

Updated on 9 March 2007 PIL

Reasons for updating

  • Change to date of revision
  • Change to side-effects
  • Change of contraindications
  • Addition of marketing authorisation holder

Updated on 9 June 2006 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 8 February 2006 SmPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 8 August 2005 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 23 June 2003 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)